Recanalization Therapies in Acute Ischemic Stroke: Pharmacological Agents, Devices, and Combinations

Table 1

Arterial occlusions and recanalization patterns in some clinical trials in acute ischemic stroke.

TRIAL			Treatment	Number of patients	Highest reported recanalization rate (%)	Assessment of recanalization
NINDS	Active		IV-TPA	312	—	None
	Control		Placebo	312	—
DIAS	Active		Desmopletase (IV)	71 (Total)	49	MRA-complete or partial recanalization
	Part-l	25 mg		16	56
		37.5/50 mg		13	46
	Part-2	62.5 mg/kg		13	23
		90 mg/kg		15	47
		125 mg/kg		14	71
	Control		Placebo	26 (Total)	19
	Part-1			16	19
	Part-2			10	20
PROACT-II (TIMI 2 $+$ 3)	Active		lAr-proUK	121	66	Cerebral angiography (TIMI 2 $+$ 3)
	Control		Placebo	59	18
EMS	Active		IV $+$ IA TPA	11	81	Cerebral angiography
	Control		Placebo $+$ IA TPA	10	50
MERCI	Active		MERCI $\pm$ Lytic			Cerebral angiography (any recanalization)
	MCA			80	45
	ICA			47	53
	VAIBA		—	14	50
	Control			—	—
CLOTBUST (at 2 hours)	Active		IV-TPA $+$ TCD	63	38	TCD
	Control		IV-TPA	63	13
TRUMBI	Active		IV-TPA $+$ Ultrasound	14	29.3	MRA
	Control		IV-TPA	12	50.0